IP Library Granted Patent US 9,824,182
Granted Patent B2
US 9,824,182 · App. 12/806,137 · Granted Nov 21, 2017

Method and system for determining whether a drug will be effective on a patient with a disease

Inventors: Heinrich Röder (Steamboat Springs, CO); Maxim Tsypin (Steamboat Springs, CO); Julia Grigorieva (Steamboat Springs, CO)
Assignee: Biodesix, Inc.
G06F19/24G06K9/6231G06K9/6276G06F19/18Y10T436/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,824,182
App. No.
12/806,137
Granted
Nov 21, 2017
Kind
B2
Abstract

A process of determining whether a patient with a disease or disorder will be responsive to a drug, used to treat the disease or disorder, including obtaining a test spectrum produced by a mass spectrometer from a serum produced from the patient. The test spectrum may be processed to determine a relation to a group of class labeled spectra produced from respective serum from other patients having the or similar clinical stage same disease or disorder and known to have responded or not responded to the drug. Based on the relation of the test spectrum to the group of class labeled spectra, a determination may be made as to whether the patient will be responsive to the drug.

Claims (7)

1. A laboratory test processing center, comprising:

one or more data storage devices storing (a) class-labeled matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF)-derived mass spectral data obtained from blood-based samples of a multitude of cancer patients, the class labels for the mass spectral data indicating whether or not a patient associated with the mass spectral data was responsive to treatment of cancer from administration of a cancer targeting drug; and (b) a multitude of MALDI-TOF-derived mass spectra of blood-based samples of a multitude of cancer patients to be tested;

a processing unit operating in accordance with a set of instructions to perform the following operations on the multitude of mass spectra of the blood-based samples of a multitude of cancer patients to be tested and the class-labeled mass spectral data:

(a) perform one or more predefined pre-processing steps on the multitude of MALDI-TOF-derived mass spectra of the blood-based samples of a multitude of cancer patients to be tested;

(b) obtain integrated intensity values of features in the mass spectra of the blood-based samples of the multitude of cancer patients to be tested at one or more predetermined m/z ranges in said mass spectra after the performance of said predefined pre-processing steps;

c) implement a classification algorithm on the integrated intensity values and the class-labeled mass spectral data, the classification algorithm assigning a class label for each of the multitude of mass spectra, wherein the classification algorithm comprises a probabilistic k-nearest neighbor classification algorithm; and

d) output the class label assigned by the classification algorithm to each of the multitude of mass spectra of the cancer patients to be tested.

Assignments (7)
SECURITY AGREEMENT Recorded Nov 22, 2022
From: BIODESIX, INC.
To: PERCEPTIVE CREDIT HOLDINGS IV, LP
Reel/Frame 061977/0919 →
RELEASE OF SECURITY INTEREST Recorded Mar 19, 2021
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
To: BIODESIX, INC.
Reel/Frame 055657/0911 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NATURE OF CONVEYANCE PREVIOUSLY RECORDED ON REEL 045450 FRAME 0503. ASSIGNOR(S) HEREBY CONFIRMS THE RELEASE OF SECURITY INTEREST. Recorded Apr 12, 2018
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: BIODESIX, INC.
Reel/Frame 045922/0171 →
SECURITY INTEREST Recorded Feb 27, 2018
From: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
To: BIODESIX, INC.
Reel/Frame 045450/0503 →
SECURITY INTEREST Recorded Feb 23, 2018
From: BIODESIX, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 045022/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 2, 2018
From: RODER, HEINRICH; TSYPIN, MAXIM; GRIGORIEVA, JULIA
To: BIODESIX INC.
Reel/Frame 044818/0967 →
SHORT-FORM PATENT SECURITY AGREEMENT Recorded Dec 3, 2013
From: BIODESIX, INC.
To: CAPITAL ROYALTY PARTNERS II L.P.; CAPITAL ROYALTY PARTNERS II - PARALLEL FUND "A" L.P.; PARALLEL INVESTMENT OPPORTUNITIES PARTNERS II L.P.
Reel/Frame 031751/0694 →
Continuity (3)
Continuation 12661129 · Mar 10, 2010
Continuation 11396328 · Mar 31, 2006
Related Publication 20100305868A1 · Dec 2, 2010